Phase 2 Brain Cancer Trial, Recruiting NCT07053033 Sponsor: M.D. Anderson Cancer Center Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT07053033
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand the study and are willing to sign a written consent form.
  • People who are willing to follow all study procedures and are available for the full duration of the study.
  • People who are 18 years of age or older.
  • People whose general health and ability to carry out daily activities meets a minimum functional threshold, as assessed using a standard medical scoring scale (confirm with trial site).
  • People who have a brain metastasis (cancer that has spread to the brain from another part of the body) that shows signs of possible regrowth on scans, and that was previously treated with a focused radiation procedure called stereotactic radiosurgery at least 3 months before joining the study.
  • People who have at least one brain lesion large enough to be measured accurately on an MRI scan (at least 5mm in size).
  • People whose tissue sample from a prior surgery or laser treatment on the lesion confirmed active tumour.
  • People who are able to safely have an MRI scan.
  • People whose treating doctor and a specialist medical team agree they are a suitable candidate for a second course of stereotactic radiosurgery.
  • People whose scans show no signs of cancer spreading along the lining of the brain or spinal cord.
  • People who have or have had another cancer, where that cancer or its treatment does not interfere with the safety or effectiveness of this study's treatment.

Who may not be able to join:

  • People whose brain metastases originated from blood cancers (such as leukaemia or lymphoma).
  • People with a psychiatric illness or personal circumstances that would make it difficult to follow the study requirements.
  • People who are pregnant, as the radiation used in this study carries potential risks to a developing baby.
  • Female patients between the start of menstrual periods and age 55 will need a pregnancy test before treatment, unless they meet one of the following exceptions: have not had a period for 12 or more consecutive months; have had surgical removal of the uterus or both ovaries; have ovarian failure confirmed by specific hormone tests and have received whole pelvic radiation therapy; or have had a permanent surgical sterilisation procedure such as tubal ligation.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Subha Perni, MD, M.D. Anderson Cancer Center

Phone: 713-563-2543

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
30 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety and Adverse Events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov